The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

Completed

• Conditions: Sarcopenia; COPD Exacerbation
• Interventions: Diagnostic Test: sarcopenia measurement

• Registration Number: NCT04885933
• Lead Sponsor: Far Eastern Memorial Hospital

Brief Summary

Chronic obstructive pulmonary disease (COPD) is more prevalent and has more impact on health status because of progressive air pollution, tobacco smoking and aging society. The COPD prevalence investigation in 2013 by phone call showed at least 6% of the population with more than 40 years-old in Taiwan. It also was the 7th ranking of death causes in Taiwan then. Apart from chronic inflammation in lung and deteriorated lung function, it had extrapulmonary complications, such as cardiovascular problems, osteoporosis and muscle wasting. The concept of sarcopenia was proposed at first in 1989. It increases the risk of falls, disability and lowering life quality. Besides, it increased the mortality risk after admission from acute ward. Thereafter, sarcopenia is one of COPD co-morbidities, which should have great impacts of COPD. The studies showed sarcopenia reduced exercise capacities and worsening dyspnea scores. On the other hand, COPD exacerbation brings significant health burden. But there is limited data about the effect on sarcopenia on COPD exacerbation. We conducted a prospective observational study. We measured skeletal muscle mass and the strength of the used hand grip within 3 days of admission and before discharge. Mortality and exacerbation in one year are the primary end-points

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-31
• Primary Completion: 2019-01-31
• Study Completion: 2020-06-21
• Status Verified: 2021-05
• Study First Submitted: 2021-05-10
• Study First Submitted QC: 2021-05-10
• Last Update Submitted: 2021-05-10
• Study First Posted: 2021-05-13
• Last Update Posted: 2021-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
COPD exacerbation	sarcopenia measurement	-

Primary Outcome Measures

Name	Time	Method
Mortality and exacerbations within 1 year of admission	1 years

Trial Locations

Locations (1)

Far Eastern Memorial Hospital; 🇨🇳 New Taipei, Taiwan